Tags

Type your tag names separated by a space and hit enter

[New antiepileptic drugs: characteristics and clinical applications].
Nihon Rinsho. 2014 May; 72(5):931-8.NR

Abstract

New antiepileptic drugs (AEDs) that have been used in many other countries for more than 10 years have only recently became available for use in Japan. Gabapentin, topiramate, lamotrigine and levetiracetam were licensed for use in Japan between 2006 and 2010. Stiripentol for Dravet syndrome and rufinamide for Lennox-Gastaut syndrome were also approved in 2012 and 2013 as orphan drugs. Clinical trials of other new AEDs such as oxcarbazepine, vigabatrin, lacosamide, and perampanel are in progress. In this review, the general characteristics of the new AEDs are discussed with regards to their effectiveness, tolerability, drug interaction, safety and mechanisms of action. The effectiveness, of the new AEDs compared with established AEDs is also discussed. Clinical applications of the new AEDs, focusing on gabapentin, topiramate, lamotrigine and levetiracetam are also discussed based on our domestic experience as well as overseas reports.

Authors

No affiliation info available

Pub Type(s)

Journal Article
Review

Language

jpn

PubMed ID

24912297

Citation

Ohtsuka, Yoko. "[New Antiepileptic Drugs: Characteristics and Clinical Applications]." Nihon Rinsho. Japanese Journal of Clinical Medicine, vol. 72, no. 5, 2014, pp. 931-8.
Ohtsuka Y. [New antiepileptic drugs: characteristics and clinical applications]. Nihon Rinsho. 2014;72(5):931-8.
Ohtsuka, Y. (2014). [New antiepileptic drugs: characteristics and clinical applications]. Nihon Rinsho. Japanese Journal of Clinical Medicine, 72(5), 931-8.
Ohtsuka Y. [New Antiepileptic Drugs: Characteristics and Clinical Applications]. Nihon Rinsho. 2014;72(5):931-8. PubMed PMID: 24912297.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [New antiepileptic drugs: characteristics and clinical applications]. A1 - Ohtsuka,Yoko, PY - 2014/6/11/entrez PY - 2014/6/11/pubmed PY - 2014/8/27/medline SP - 931 EP - 8 JF - Nihon rinsho. Japanese journal of clinical medicine JO - Nihon Rinsho VL - 72 IS - 5 N2 - New antiepileptic drugs (AEDs) that have been used in many other countries for more than 10 years have only recently became available for use in Japan. Gabapentin, topiramate, lamotrigine and levetiracetam were licensed for use in Japan between 2006 and 2010. Stiripentol for Dravet syndrome and rufinamide for Lennox-Gastaut syndrome were also approved in 2012 and 2013 as orphan drugs. Clinical trials of other new AEDs such as oxcarbazepine, vigabatrin, lacosamide, and perampanel are in progress. In this review, the general characteristics of the new AEDs are discussed with regards to their effectiveness, tolerability, drug interaction, safety and mechanisms of action. The effectiveness, of the new AEDs compared with established AEDs is also discussed. Clinical applications of the new AEDs, focusing on gabapentin, topiramate, lamotrigine and levetiracetam are also discussed based on our domestic experience as well as overseas reports. SN - 0047-1852 UR - https://www.unboundmedicine.com/medline/citation/24912297/[New_antiepileptic_drugs:_characteristics_and_clinical_applications]_ L2 - https://medlineplus.gov/epilepsy.html DB - PRIME DP - Unbound Medicine ER -